All In Biotech

Drug Trial Radar · NCT07090330

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 18, 2025

Primary completion

Mar 25, 2026

Study completion May 2027

Sponsor

Lead sponsor
Oruka Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • ORKA-001 Induction DoseDrug

    ORKA-001 Induction Dose, administered by subcutaneous (SC) injection

  • PlaceboOther

    Placebo administered by subcutaneous (SC) injection

  • ORKA-001 Maintenance DoseDrug

    ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Time frame: Week 16

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Oruka Therapeutics Investigative Site

    Fountain Valley, California

  • Oruka Therapeutics Investigative Site

    Los Angeles, California

  • Oruka Therapeutics Investigative Site

    San Diego, California

  • Oruka Therapeutics Investigative Site

    Santa Ana, California

  • Oruka Therapeutics Investigative Site

    Santa Monica, California

  • Oruka Therapeutics Investigative Site

    Cromwell, Connecticut

  • Oruka Therapeutics Investigative Site

    Miami, Florida

  • Oruka Therapeutics Investigative Site

    Rolling Meadows, Illinois

  • Oruka Therapeutics Investigative Site

    Bowling Green, Kentucky

  • Oruka Therapeutics Investigative Site

    Rockville, Maryland

  • Oruka Therapeutics Investigative Site

    Boston, Massachusetts

  • Oruka Therapeutics Investigative Site

    Detroit, Michigan

  • Oruka Therapeutics Investigative Site

    New York, New York

  • Oruka Therapeutics Investigative Site

    New York, New York

  • Oruka Therapeutics Investigative Site

    Portland, Oregon

  • Oruka Therapeutics Investigative Site

    Norfolk, Virginia

  • Oruka Therapeutics Investigative Site

    Milwaukee, Wisconsin

  • Oruka Therapeutics Investigative Site

    Edmonton, Alberta, Canada

  • Oruka Therapeutics Investigative Site

    Edmonton, Alberta, Canada

  • Oruka Therapeutics Investigative Site

    Surrey, British Columbia, Canada

  • Oruka Therapeutics Investigative Site

    Hamilton, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    London, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Markham, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Peterborough, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Toronto, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Waterloo, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.